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Abstract The aim of this study was to determine the
prevalence and severity of fatigue in long-term survivors
with a low-grade glioma (LGG), and to analyze the rela-
tionship between fatigue and demographic variables,
disease duration, tumor characteristics, former tumor
treatment modalities, antiepileptic drug (AED) use, self-
reported concentration, motivation, and activity. Fifty-four
patients with stable disease (age range, 25–73 years) who
were diagnosed and treated more than 8 years ago were
included in this study. Fatigue was analyzed with the
Checklist Individual Strength (CIS). Thirty-nine percent of
the LGG patients were severely fatigued, with older
patients being most affected. Severe fatigue was associated
with AED use, and with reduced self-reported concentra-
tion, motivation, and activity. No relation was found
between fatigue and gender, histology, tumor laterality,
disease duration, type of neurosurgical intervention and
radiation treatment. Fatigue is a severe problem in a large
proportion of long-term surviving LGG patients.
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Introduction
Low-grade gliomas are primary malignant brain tumors of
glial origin [1]. The median survival time for patients with
LGG ranges from 5 to 15 years [2, 3], and some patients
may survive in a stable state for many years after the
diagnosis and initial treatment. Frequent symptoms expe-
rienced by patients with LGG are epileptic seizures and
cognitive disturbances [4, 5].
Fatigue is frequently reported by patients with cancer
[6]. During treatment, in advanced stages of the disease,
and after curative treatment, fatigue has been described as a
major problem. In the last 10 years, the amount of research
on the relationship between cancer and fatigue has
increased remarkably [7]. However, little is known about
the variables associated with the initiation and persistence
of cancer-related fatigue [8]. The assumption is that fatigue
develops during the treatment phase, but later on there
seems to be no clear relationship between persistent fatigue
and initial disease and treatment variables [7–11]. Esti-
mations of fatigue during treatment of cancer range from
25% to 75% [7]. In addition, based on several cross-sec-
tional and longitudinal studies, fatigue seems to be a
problem for a considerable number of cancer survivors [7,
8, 11–14].
Clinical practice suggests that fatigue is also important
in glioma patients. However, the level of fatigue and its
associated factors have not been studied extensively in
LGG patients. Studies assessing fatigue in this patient
group mostly use only a limited number of items from a
quality of life instrument [15–17]. However, the most
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comprehensive approach to assess fatigue would be using a
multidimensional instrument [18], because fatigue is a
multidimensional concept with several modes of expres-
sion (physical, cognitive, and affective) [7]. In one cross-
sectional study, fatigue was assessed in 39 LGG patients
with help of the European Organization for Research and
Treatment of Cancer (EORTC) Core Quality of Life
Questionnaire, containing three items for fatigue. The
majority of these patients reported tiredness and about half
of them had sleep disturbances [15]. In another quality of
life study, LGG patients scored higher on the subscale
fatigue compared to control subjects, using the Profile of
Mood States to measure affective disturbances [16].
In this study the following research questions are
addressed: (1) What is the prevalence and severity of
fatigue in LGG patients? (2) Is fatigue associated with
demographic variables (age and gender), disease duration,
tumor characteristics (histology and tumor laterality), for-
mer tumor treatment modalities (type of neurosurgical
intervention, post-surgery radiotherapy), the use of AEDs,
or with self-reported concentration, reduced motivation and
activity?
Methods
Patients
Fifty-eight patients aged 25–73 (mean 48) years with a
LGG diagnosed and treated 8–29 years ago were approa-
ched for this study. These patients were part of a group of
LGG patients recruited between 1997 and 2000 for a large
nationwide study into the neuropsychological status and
quality of life [5]. We exclusively approached long-term
survivors of a histologically proven LGG without signs of
tumor recurrence, and who already participated in a follow-
up study on cognition and quality of life between 2004 and
2005.
Recruitment procedure
We sent a fatigue questionnaire to the 58 patients, together
with a letter from the research coordinator in the summer of
2006, explaining the intention of the study. Furthermore, an
informed consent form was enclosed. Those patients who
were willing to participate in the study were asked to
complete the questionnaire, and sign the informed consent
form at home.
Measures
Fatigue and fatigue related symptoms were measured with
the Checklist Individual Strength (CIS). The CIS is a
multidimensional fatigue scale; it measures four aspects of
fatigue during the previous 2 weeks, namely: fatigue
severity (eight items), concentration problems (five items),
reduced motivation (four items), and reduced activity
(three items) [19, 20]. Each item is scored on a seven-point
Likert scale. Total scores of every subscale are obtained by
adding the individual items, with high scores indicating a
high level of fatigue, a high level of concentration prob-
lems, low motivation, and a low level of activity. Patients
with a score of 35 or higher on the fatigue severity subscale
are considered to be severely fatigued. This cut-off value is
based on data obtained in patients with chronic fatigue
syndrome [20].
Statistical analysis
Data analysis was accomplished using SPSS software,
version 12.0. As a result of small sample size we had to
use a non-parametric approach when selecting statistical
methods. Mann–Whitney tests were conducted to test the
differences between groups. To test the relation between
fatigue and age, disease duration, self-reported concen-
tration, motivation and activity, comparisons were made
between severely fatigued (CIS C 35) and non-severely
fatigued (CIS \ 35) LGG patients. The level of statisti-
cal significance for all tests was set at P value less than
0.05.
Results
Patient characteristics
Fifty-four of the 58 patients we approached (93%) com-
pleted and returned the CIS questionnaire. One patient was
unable to participate due to foreign residence. One patient
declined participation in the study, and the reasons of two
other non-participants are unknown. Non-participants did
not differ from the participants with respect to gender,
histology, disease duration, type of neurosurgical inter-
vention, and AED use. On the other hand, the non-
participants were slightly younger (mean 43.5 years), and
none of them had received radiotherapy. Information about
the characteristics of the LGG patients is listed in Table 1.
Fatigue prevalence and severity
The mean CIS-fatigue severity score of the sample LGG
patients was 28.2 (SD 15.5). The CIS-fatigue cut-off score
of C35 for severe fatigue was crossed by 21 patients.
Hence, 39% of the LGG patients experienced severe fati-
gue. The remaining 33 patients were classified as non-
severely fatigued.
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Fatigue related to patient, tumor and treatment
characteristics
To test the relationship between age, disease duration, and
fatigue, comparisons were made between severely fatigued
(CIS C 35, n = 21) and non-severely fatigued (CIS \ 35,
n = 33) LGG patients. Severely fatigued patients were
older than the non-severely fatigued patients (Mann–
Whitney, P = 0.012). We did not find any differences in
disease duration for severely and non-severely fatigued
patients (Mann–Whitney, P = 0.404). Fatigue severity was
not related to gender (Mann–Whitney, P = 0.640), and no
association could be established between histological
diagnosis (astrocytoma and oligodendroglioma) and fatigue
severity (Mann–Whitney, P = 0.766). Due to the small
number of patients with mixed glioma (oligoastrocytoma),
data of these patients were excluded from the analyses.
Furthermore, the association between tumor laterality and
fatigue severity was investigated, while excluding midline
tumor locations because of the small sample size (n = 2).
Results of a Mann–Whitney test indicated that there was no
association between tumor laterality and fatigue severity
(P = 0.435).
No association was found between type of neurosurgical
intervention and fatigue severity (Mann–Whitney,
P = 0.081). Approximately half of the LGG patients
(n = 29) received radiotherapy. Again, no effect was found
between former radiation treatment and fatigue severity
(Mann–Whitney, P = 0.993). However, patients treated
with AEDs were more fatigued (Mann–Whitney,
P = 0.004), irrespective of the use of mono- or poly-
therapy (Mann–Whitney, P = 0.738) (Table 2).
Fatigue related problems: concentration, motivation
and activity
To test the association between fatigue and self-reported
concentration, motivation and activity, comparisons were
made between severely fatigued (CIS C 35) and non-
severely fatigued (CIS \ 35) LGG patients. Severely fati-
gued LGG patients reported reduced motivation, a lower
Table 1 Low-grade glioma patient group (n = 54): characteristics
Characteristics Data
Mean agea 48 (SD 11.8, range 25–73)
Gender: M 28 (52%)
Mean level of educationb 4.1 (SD 2.0, range 1–8)
Mean disease durationa 15.0 (SD 4.0, range 8–29)
Histological diagnosis
Astrocytoma 39 (72%)
Oligodendroglioma 10 (19%)
Oligoastrocytoma 5 (9%)
Tumor location
Left-sided 32 (59%)
Right-sided 20 (37%)
Midline 2 (4%)
Neurosurgical intervention
Biopsy 17 (31%)
Resection 37 (69%)
Radiotherapy
Yes 29 (54%)
No 25 (46%)
Antiepileptic drug use
Yes 26 (48%)
No 26 (48%)
Missing 2 (4%)
Type of antiepileptic drug use
Monotherapy 14 (54%)
Polytherapy 12 (46%)
Data are number (%) of patients, unless otherwise indicated
a Years
bEducation was assessed by a Dutch scoring system ranging from
unfinished primary education (level 1) to university education (level 8)
Table 2 Tumor and treatment characteristics in relation to fatigue
Variables N Mean CIS-fatigue (SD) P-valuea
Histological diagnosis
Astrocytoma 39 27.2 (15.2) 0.766
Oligodendroglioma 10 29.1 (18.5)
Oligoastrocytomab 5 34.6 (12.3)
Tumor location
Left-sided 32 27.4 (15.5) 0.435
Right-sided 20 30.7 (15.8)
Midlineb 2 17.5 (13.4)
Neurosurgical intervention
Biopsy 17 33.8 (15.7) 0.081
Resection 37 25.7 (15.0)
Radiotherapy
Yes 29 28.3 (15.0) 0.993
No 25 28.2 (16.4)
Antiepileptic drug use
Yes 26 34.5 (14.6) 0.004
No 26 22.2 (13.9)
Missing 2
Type of antiepileptic drug
Monotherapy 14 33.6 (14.6) 0.738
Polytherapy 12 35.7 (15.2)
Abbreviation: CIS, Checklist Individual Strength
a Mann–Whitney tests were conducted to analyze the association
between fatigue and tumor and treatment characteristics
b Variables which were excluded in testing
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level of activity, and more problems with concentration
(Mann–Whitney, P \ 0.001) (Table 3).
Discussion
In this study, we found that 39% of long-term survivors
with a LGG experience severe fatigue. Few studies asses-
sed fatigue in LGG patients [15–17]. In one quality of life
study, fatigue is mentioned as a problem for the majority of
glioma patients [15]. The current study confirms these
results. However, the 39% prevalence rate of severe fatigue
is the highest found among all cancer patients measured
with the CIS. Only the percentage of severe fatigue in a
sample of breast cancer survivors (38%) 2.5 years after
curative treatment equals our findings [12]. This percentage
declines to 24% after a follow-up period of 2 years. Other
cross-sectional and longitudinal studies investigating the
prevalence and course of fatigue show similar results,
revealing that fatigue continues to decrease during the first
years after curative treatment. For about a quarter of cancer
survivors fatigue remains a problem [21]. Since the LGG
patients in our study finished their treatment more than
8 years ago, the percentage of severe fatigue of nearly 40%
is remarkably high. It is important to note that the LGG
population differs from non-glioma cancer populations. In
these non-glioma cancer studies, patients are considered to
be disease-free. In contrast, LGG patients are considered to
be never completely free of disease [5]. As a consequence,
being confronted with a life-threatening illness can lead to
feelings of depression and anxiety for the future, which
both may be correlated with fatigue [6, 22–27]. Further-
more, LGG patients have specific cognitive problems [5],
which presumably may also be related to fatigue.
Moreover, our results show that fatigue is related to
other problems. Severely fatigued LGG patients have more
problems with regard to self-reported concentration, and
they experience reduced motivation and activity. These
results are comparable to the extent of problems
experienced by patients with chronic fatigue syndrome.
However, compared to severely fatigue disease-free cancer
patients, the LGG patients in our study report more prob-
lems with concentration [6].
In this study no association was found between gender
and fatigue severity, but fatigue complaints were more
severe in older LGG patients. Also in testicular cancer
patients [28] and in patients with hematological malig-
nancies [29, 30] the older patients reported more fatigue,
whereas in breast cancer patients the younger participants
were more fatigued [31].
Furthermore, we found no relation between fatigue
severity, tumor characteristics, and former tumor treatment.
In one prospective quality of life study it was demonstrated
that patients with a high-grade glioma in the right hemi-
sphere were more fatigued than those with a left-sided
tumor [32]. However, in most studies, no associations were
found between tumor-related variables and fatigue inten-
sity with regard to disease duration [23, 25, 26, 29, 33–35],
type of cancer [27, 36], disease stage at diagnosis [23, 25–
27, 33, 37], size of the original tumor [25, 26, 37], number
of nodes involved [25] and tumor recurrence [33].
Literature data suggest that fatigue arises during the
active treatment phase in nearly all cancer patients, but
little is known about the etiology of persistent fatigue [7–
11]. Some studies suggest that patients with more aggres-
sive former treatments are more at risk for persistent
fatigue [21, 31, 38, 39], but others do not find a strong
association between initial cancer treatment and off-treat-
ment fatigue [7–11]. In our study, no differences in fatigue
severity were observed for patients who had a biopsy and
for patients who underwent a resection. Furthermore, no
differences were observed in patients with or without prior
radiotherapy. However, fatigue was significantly more
pronounced in patients that used AEDs.
This study has its limitations. Small sample size was the
reason we had to exclude some variables from the analyses
(i.e., oligoastrocytomas, tumors in midline locations).
Furthermore, we have no data of current epileptic activity
in this study. Therefore, we are not able to distinguish
whether seizures or the use of AEDs contributed to the
experience of fatigue. It would be very interesting to study
a larger group of glioma patients with emphasis on fatigue,
AED use, and epilepsy burden. Nonetheless, we conclude
that fatigue is a major problem in LGG patients. The cur-
rent study demonstrates that almost 40% of long-term
survivors with a LGG experience severe fatigue. These
findings are important because fatigue has a serious impact
on quality of life [40]. Furthermore, a decreased level of
quality of life in LGG patients is significantly related to
shorter survival [41]. Assessment and treatment of fatigue
in LGG patients need to be further investigated, potentially
resulting in improvement of quality of life.
Table 3 Fatigue-related problems: concentration, motivation and
activity
CIS-subscales Non-severely
fatigued
patients
(n = 33)
Severely
fatigued
patients
(n = 21)
P-valuea
Mean CIS-concentration (SD) 14.5 (7.8) 26.1 (7.5) \0.001
Mean CIS-motivation (SD) 9.5 (4.8) 17.0 (6.8) \0.001
Mean CIS-activity (SD) 6.4 (3.9) 14.5 (5.8) \0.001
Abbreviation: CIS, Checklist Individual Strength
a The Mann–Whitney test was conducted to test the differences
between non-severely and severely fatigued LGG patients
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